Orbital and Eyelid B-Cell Lymphoma: A Multicenter Retrospective Study.
eyelid lymphoma
ocular adnexal lymphoma
ocular lymphoma prognosis
ocular lymphoma treatment
orbital lymphoma
orbital neoplasms
precision medicine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Sep 2020
07 Sep 2020
Historique:
received:
06
08
2020
revised:
30
08
2020
accepted:
03
09
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
epublish
Résumé
The aim of this study was to analyze patients diagnosed, staged and treated for orbital and eyelid B-cell lymphoma (OEL). One hundred and forty-one cases of OEL were included in this study. Primary endpoints were to analyze the histopathologic findings, the main risk factors and the type of treatment and to correlate them with recurrence of OEL. The secondary endpoint was to determine the progression-free survival (PFS) time. Extranodal marginal zone B-cell lymphoma was the most frequent subtype (66%), followed by small lymphocytic lymphoma (12.7%), diffuse large B-cell lymphoma (DLBCL) (9.2%), follicular lymphoma (6.6%), mantle cell lymphoma (4.3%) and Burkitt lymphoma (1.2%). The probability of relapse was influenced by the histopathologic subtype DLBCL (OR = 7.7, 95% CI 1.8-32.3) and treatment with chemotherapy (OR = 14.9, 95% CI 2.6-83.7). Multivariate analysis showed that the histopathologic subtype DLBCL and chemotherapy treatment retained statistical significance for a poorer PFS, with hazard ratios of 8.581 ( Five lymphoma subtypes were found in patients with OEL. The histopathologic subtype and the type of treatment were found to be the main factors influencing treatment outcome.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to analyze patients diagnosed, staged and treated for orbital and eyelid B-cell lymphoma (OEL).
METHODS
METHODS
One hundred and forty-one cases of OEL were included in this study. Primary endpoints were to analyze the histopathologic findings, the main risk factors and the type of treatment and to correlate them with recurrence of OEL. The secondary endpoint was to determine the progression-free survival (PFS) time.
RESULTS
RESULTS
Extranodal marginal zone B-cell lymphoma was the most frequent subtype (66%), followed by small lymphocytic lymphoma (12.7%), diffuse large B-cell lymphoma (DLBCL) (9.2%), follicular lymphoma (6.6%), mantle cell lymphoma (4.3%) and Burkitt lymphoma (1.2%). The probability of relapse was influenced by the histopathologic subtype DLBCL (OR = 7.7, 95% CI 1.8-32.3) and treatment with chemotherapy (OR = 14.9, 95% CI 2.6-83.7). Multivariate analysis showed that the histopathologic subtype DLBCL and chemotherapy treatment retained statistical significance for a poorer PFS, with hazard ratios of 8.581 (
CONCLUSIONS
CONCLUSIONS
Five lymphoma subtypes were found in patients with OEL. The histopathologic subtype and the type of treatment were found to be the main factors influencing treatment outcome.
Identifiants
pubmed: 32906630
pii: cancers12092538
doi: 10.3390/cancers12092538
pmc: PMC7563111
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ocul Oncol Pathol. 2017 Sep;3(3):181-187
pubmed: 29134184
Acta Ophthalmol. 2015 Mar;93(2):184-91
pubmed: 25125069
Ann Oncol. 2013 Apr;24(4):857-77
pubmed: 23425945
JAMA Ophthalmol. 2014 Jul;132(7):851-8
pubmed: 24763920
Ophthalmology. 2018 Jan;125(1):127-136
pubmed: 28712656
Am J Ophthalmol. 2017 May;177:58-68
pubmed: 28209503
Blood. 2002 Jun 15;99(12):4265-75
pubmed: 12036852
Am J Surg Pathol. 2007 Feb;31(2):170-84
pubmed: 17255761
Am J Ophthalmol. 2012 Jul;154(1):87-98.e1
pubmed: 22503694
Ann Oncol. 2017 Dec 1;28(12):3109
pubmed: 28327933
Eye Vis (Lond). 2019 Jul 27;6:22
pubmed: 31372366
J Clin Oncol. 2003 Nov 15;21(22):4157-64
pubmed: 14615444
Blood. 1991 Jul 15;78(2):259-63
pubmed: 2070063
Ophthalmology. 1998 Aug;105(8):1430-41
pubmed: 9709754
Eye (Lond). 2013 Feb;27(2):180-9
pubmed: 23222560
JAMA Ophthalmol. 2015 Feb;133(2):165-73
pubmed: 25393033
Acta Ophthalmol. 2009 Feb;87 Thesis 1:1-20
pubmed: 19178392
Hematology Am Soc Hematol Educ Program. 2001;:194-220
pubmed: 11722985
Eur J Ophthalmol. 2013 May-Jun;23(3):344-55
pubmed: 23397158
Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):118-130
pubmed: 28288706
Am J Hematol. 2003 Jun;73(2):87-96
pubmed: 12749009
CA Cancer J Clin. 2016 Sep;66(5):370-4
pubmed: 26784705
Infect Agent Cancer. 2012 Apr 02;7:8
pubmed: 22472082
J Natl Compr Canc Netw. 2019 Jan;17(1):12-20
pubmed: 30659125
Leukemia. 2004 Oct;18(10):1722-6
pubmed: 15356642
Br J Ophthalmol. 2008 Apr;92(4):446-8
pubmed: 18369056
Ophthalmol Clin North Am. 2005 Mar;18(1):187-97, x
pubmed: 15763204
Leukemia. 2005 Apr;19(4):652-8
pubmed: 15703784
Immun Ageing. 2018 Sep 21;15:22
pubmed: 30258468
J Pathol. 2006 Jul;209(3):344-51
pubmed: 16583361
Blood. 2006 Sep 1;108(5):1451-60
pubmed: 16638927
Ophthalmology. 2013 Sep;120(9):1915-9
pubmed: 23664470
Pathol Res Pract. 1991 Jan;187(1):78-84
pubmed: 2027825
Arch Ophthalmol. 2010 Oct;128(10):1295-9
pubmed: 20937999
Br J Ophthalmol. 2020 Mar;104(3):357-362
pubmed: 31177189
Br J Ophthalmol. 2009 Aug;93(8):1047-51
pubmed: 19429588
Arch Ophthalmol. 2002 Sep;120(9):1225-7
pubmed: 12215104
Ophthalmology. 2003 Jun;110(6):1245-54
pubmed: 12799255
Blood. 2003 Aug 1;102(3):1012-8
pubmed: 12676782
Ophthalmology. 2005 Jan;112(1):114-9
pubmed: 15629830
Br J Ophthalmol. 2020 Apr 23;:
pubmed: 32327417
Acta Ophthalmol. 2013 Mar;91(2):163-9
pubmed: 22551232
JAMA Ophthalmol. 2016 Apr;134(4):406-14
pubmed: 26891973
N Engl J Med. 1994 Jul 14;331(2):74-80
pubmed: 8208268
Cytojournal. 2010 Oct 11;7:20
pubmed: 20976208
Blood. 1998 Nov 1;92(9):3152-62
pubmed: 9787151
JAMA Ophthalmol. 2017 Dec 1;135(12):1367-1374
pubmed: 29121219
Leuk Lymphoma. 2001 Jun;42(1-2):207-14
pubmed: 11699208
Arch Pathol Lab Med. 2003 Sep;127(9):1148-60
pubmed: 12946230
Am J Ophthalmol. 2019 Mar;199:44-57
pubmed: 30419193
Surv Ophthalmol. 2018 May - Jun;63(3):381-388
pubmed: 28837797